[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100354078":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":68,"collaborators":70,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":12,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":12,"enrollmentInfo":85,"targetDuration":12,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":51,"whyStopped":12,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Clinact","OTHER",[8,13,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","NO_INTERVENTION","no home non-invasive ventilation (NIV), only hospital NIV",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Non-targeted home NIV","ACTIVE_COMPARATOR","Nocturnal home non-invasive ventilation (NIV)",[18],"Device: home ventilators",{"label":20,"type":15,"description":21,"interventionNames":22},"Targeted home NIV","Nocturnal home non-invasive ventilation (NIV) with high monitoring",[18],{"label":24,"type":15,"description":25,"interventionNames":26},"Rescue home NIV","home non-invasive ventilation (NIV) on demand",[18],[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":12},"DEVICE","home ventilators","The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.",[14,24,20],[34],{"name":35,"affiliation":36,"role":37},"Jesus Gonzalez, MD","Hôpital Pitié Salpêtrière-Charles Foix, Paris, France ,","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":12,"email":43},"Angèle Guilbot","CONTACT","+33-180-13-15-19","angele.guilbot@multihealthgroup.com",{"name":45,"role":41,"phone":46,"phoneExt":12,"email":47},"Nathalie Gagne","+33-180-13-14-70","nathalie.gagne@clinact.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Groupe Hospitalier Pitié Salpêtrière-Charles Foix","RECRUITING","Paris","Île-de-France Region","75651","France","FR",{"type":58,"coordinates":59},"Point",[60,61],2.3488,48.85341,{"lat":61,"lon":60},[64],{"name":65,"role":41,"phone":66,"phoneExt":12,"email":67},"Jesus² GONZALES-EBERMEJO, Professor","+33 1 42 16 78 59","jesus.gonzalez@aphp.fr",{"type":69,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[71,73],{"name":72,"class":6},"Assistance Publique - Hôpitaux de Paris",{"name":74,"class":75},"Fondation du Souffle","UNKNOWN","100354078","respiratory-support-in-chronic-obstructive-pulmonary-disease-copd-patients-100354078",false,"NCT03890224","Respiratory Support in Chronic Obstructive Pulmonary Disease (COPD) Patients","Respiratory Support in Chronic Obstructive Pulmonary Disease (COPD) Patients After Acute Exacerbation With Monitoring the Quality of Support","Inclusion Criteria:\n\n* 1\\) Patients with COPD, GOLD C or D and Forced expiratory volume in one second (FEV1)\\\u003C65%;\n* 2\\) AHRF (pH\\\u003C7,35 and PaCO2≥45mm Hg (≥6kPa) treated more than 24h with Ventilation (non-invasive or invasive);\n* 3\\) 48h to 2 weeks with pH\\>7.35, and PaCO2\\>45 (\\>6kPa) after NIV withdrawal, during daytime at rest without oxygen or ventilatory support (or with O2 if patients are not able to avoid O2 with immediate desaturation below 80%).\n\nExclusion Criteria:\n\n1. Patient treated with chronic NIV or continuous positive airway pressure (CPAP) device, with ongoing treatment;\n2. Primary diagnosis of restrictive lung disease causing hypercapnia i.e. obesity hypoventilation and chest wall disease, however these patients will be included if the \"FEV1\u002FForced vital capacity (FVC)\" ratio is \\\u003C60% and the FEV1 \\\u003C50% if the predominant defect is considered to be obstructive by the center clinician;\n3. BMI \\> 35 kg\u002Fm2;\n4. Sedative medication causing hypercapnia (\\> 3 drugs or more than 20mg of morphine\u002Fday);\n5. Polygraphic diagnosis of Obstructive Sleep Apnoea Syndrome (AHI\\>30\u002Fh (French criteria);\n6. Cognitive impairment that would prevent informed consent into the trial\n7. Pregnancy;\n8. Tobacco use \\\u003C 10 pack-year;\n9. Psychiatric disease necessitating anti-psychotic medication, ongoing treatment for drug or alcohol addiction, persons of no fixed abode post-discharge;\n10. Unstable coronary artery syndrome;\n11. Age \\\u003C18 years;\n12. Inability to comply with the protocol;\n13. Expected survival\\\u003C12 months due to any situation other than COPD disease;\n14. Duration of ICU stay\\>10 days;\n15. No affiliated to national health insurance;\n16. Measure of legal protection (guardianship, wardship or judicial protection) for patients over the age of majority.","ALL","18 Years",{"count":86,"type":87},400,"ESTIMATED","INTERVENTIONAL",[90],"NA","The hypothesis of this study is that any of 3 modalities of home non- invasive ventilation (NIV) compared to 'no NIV' (=hospital NIV) will reduce re-admission to hospital or death in COPD patients who remain persistently hypercapnic following an exacerbation requiring NIV.",[93,94],"Chronic Obstructive Pulmonary Disease","COPD Exacerbation",[96],"Respiratory Support","2024-06-17",{"date":99,"type":100},"2024-06-20","ACTUAL",{"date":102,"type":100},"2019-07-04",{"date":104,"type":87},"2027-02-28",{"name":5,"class":6},1]